The Honourable Arthur T. Porter brings a unique blend of healthcare, finance and multi-sector experience to business leadership.
Dr. Porter received his early education in Sierra Leone and Kenya, East Africa. After attending the University of Sierra Leone, he transferred to Cambridge University in England, where he received his B.A. in anatomy, M.A. in natural sciences and his Medical degree. Later, Dr. Porter earned his M.B.A. from the University of Tennessee and certificates in Management from Harvard University and the University of Toronto. He was also bestowed a Fellowship and Diplomate status in Healthcare Administration from the American Academy of Medical Administrators. His major areas of academic endeavour relate to the medical uses of radioactive isotopes and the treatment of prostate cancer.
Dr. Porter’s extensive international background includes medical practice, business and academic leadership positions in Canada, Europe, Africa and the United States. He has also served as a Consultant to the World Health Organization and World Bank, and worked to establish international research and treatment programs in Turkey, India, Yemen and the GCC, the Caribbean, Brazil, Liberia, and throughout Europe. Dr. Porter opened the first state-of-the-art cancer centre in the Commonwealth of the Bahamas. He serves on the Editorial Board of 13 scientific journals and has to his credit more than 300 scholarly works in peer-reviewed journals, chapters in books and in conference proceedings. He is credited with introducing several novel concepts to radiation therapy. He is a frequent speaker at universities and medical conferences throughout the world.
In 1999, Dr. Porter was named CEO of the Detroit Medical Center, a US$1.6 billion health system, which is also one of the United States’ largest urban systems and the largest non-government employer in Detroit.
In February 2004, Dr. Porter was appointed Director General and CEO of the McGill University Health Centre (www.muhc.ca) in Montréal, Canada. With five teaching hospitals affiliated with McGill University and a sixth hospital, the MUHC is one of the most world’s foremost academic health centres with over 1,300 clinicians and some 14,000 professionals, researchers and other personnel. In July 2004, the MUHC received government approval for its Redevelopment Project. On three campuses with a value of over CAN$2 billion, this project — being completed in conventional and public-private-partnership mode — is one of the largest in Canada. As part of this project, the Research Institute of the MUHC was awarded $250 million in funding from the Canada Foundation for Innovation, the Government of Québec and donors, a testament to the institution’s leadership, vision, the value of its research, and the quality of its investigators.
Dr. Porter is a Past President of the American Brachytherapy Society; the American College of Oncology Administrators; the American Cancer Society (Great Lakes); and the American College of Radiation Oncology. He has also served as Chairman of the Board of Chancellors of the American College of Radiation Oncology and on the Board of Scientific Counselors of the National Cancer Institute (USA). Between 2006 and 2008, Dr. Porter served on the Governing Council of the Canadian Institutes of Health Research (CIHR). In 2008, Dr. Porter was appointed to a life term as a member of the Queen’s Privy Council for Canada while Prime Minister Stephen Harper appointed him to Canada’s Security and Intelligence Review Committee (SIRC). In 2010, he was appointed Chairman of the SIRC.
Dr. Porter continues to exploit his finance and business background. Among other courses, he teaches part of a M.B.A. course at the University of Tennessee (Mergers and Acquisitions) and at McGill’s School of Business Administration (Leadership). He consults regularly with several major companies in the Airline, Mining and Energy sectors regarding HR and logistic challenges, and is an Advisor to the President of the Republic of Sierra Leone. He currently serves on the Board of Directors and the Audit Committee of the Munder Funds, a multi-billion-dollar mutual fund complex (www.munder.com); is Chairman of CancerpartnersUK, a cancer treatment provider in the UK (www.cancerpartnersuk.org ); and is a member of the Board of Directors of Air Canada (www.aircanada.ca), chairing its Governance and Nominating committees. He is Chairman of the Sierra Leone-domiciled Calone Mining Company (www.calonemining.com), and is a member of the Board of Golden Valley Mines (www.goldenvalleymines.com), a TSX-V listed exploration company.